Among these, the Adjuvant Paclitaxel and Trastuzumab (APT) trial notably reported a 3-year invasive disease-free survival (iDFS) rate of 98.7%, achieved with weekly paclitaxel combined with trastuzumab (TH regimen) in patients with node-negative, HER2-positive breast cancer [3]. Here, ERBB2 is linked to breast carcinoma.